专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO9963976A3 LIVER-SELECTIVE GLUCOCORTICOID ANTAGONIST FOR TREATING DIABETES 审中-公开
标题翻译：用于治疗糖尿病的肝脏选择性GLUCOCORTICOID ANTAGONIST
公开(公告)号：WO9963976A3
公开(公告)日：2001-12-20
申请号：PCT/IB9901175
申请日：1999-06-07
申请人： KAROBIO AB , APELQVIST THERESA , EFENDIC SUAD
发明人： APELQVIST THERESA , EFENDIC SUAD
IPC分类号： A61K45/00 , A61K31/00 , A61K31/155 , A61K31/192 , A61K31/426 , A61K31/64 , A61K38/28 , A61K45/06 , A61P3/10 , A61P43/00 , C07C57/58 , A61K31/19
CPC分类号： A61K31/00
摘要： Use of a liver-selective glucocorticoid antagonist, preferably the compound having formula (I) in the preparation of a pharmaceutical composition for the treatment of diabetes. A composition for the treatment of diabetes containing such a glucocorticoid antagonist, and a method of treating diabetes using the composition.
摘要翻译：使用肝选择性糖皮质激素拮抗剂，优选具有式（I）的化合物在制备用于治疗糖尿病的药物组合物中。用于治疗含有这种糖皮质激素拮抗剂的糖尿病的组合物，以及使用该组合物治疗糖尿病的方法。

2. 发明申请

WO03028626A2 A METHOD OF REDUCING MORTALITY AND MORBIDITY ASSOCIATED WITH CRITICAL ILLNESSES 审中-公开
标题翻译：减少与关键伤害相关的死亡率和死亡率的方法
公开(公告)号：WO03028626A2
公开(公告)日：2003-04-10
申请号：PCT/US0228123
申请日：2002-09-19
申请人： LILLY CO ELI , EFENDIC SUAD , JAKUBOWSKI JOSEPH ANTHONY
发明人： EFENDIC SUAD , JAKUBOWSKI JOSEPH ANTHONY
IPC分类号： A61K38/26 , A61P11/00 , A61P11/08 , A61P11/16 , A61P31/04 , A61K
CPC分类号： A61K38/26
摘要： This invention relates to the use of glucagon-like peptide (GLP-1) compounds to reduce the mortality and morbidity associated with critical illnesses wherein a patient is predisposed to or suffers from some type of respiratory distress.
摘要翻译：本发明涉及胰高血糖素样肽（GLP-1）化合物在降低与患有易患某种类型的呼吸窘迫的危重疾病相关的死亡率和发病率的用途。

3. 发明申请

WO0016797A3 USE OF GLP-1 OR ANALOGS IN TREATMENT OF STROKE 审中-公开
标题翻译：使用GLP-1或模拟物进行治疗
公开(公告)号：WO0016797A3
公开(公告)日：2000-05-25
申请号：PCT/US9922026
申请日：1999-09-22
申请人： LILLY CO ELI , EFENDIC SUAD
发明人： EFENDIC SUAD
IPC分类号： A61K38/04 , A61K38/26 , A61P3/10 , A61P9/10 , A61P25/00
CPC分类号： A61K38/26
摘要： This invention provides a method of reducing mortality and morbidity associated with stroke. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.
摘要翻译：本发明提供了降低与中风相关的死亡率和发病率的方法。 GLP-1，GLP-1类似物或GLP-1衍生物以有效使血糖正常化的剂量施用。

4. 发明申请

WO9941411A3 METHOD FOR DIAGNOSIS AND TREATMENT OF DISORDERS OF CARBOHYDRATE METABOLISM 审中-公开
标题翻译：诊断和治疗碳水化合物代谢紊乱的方法
公开(公告)号：WO9941411A3
公开(公告)日：1999-09-30
申请号：PCT/SE9900177
申请日：1999-02-11
申请人： EFENDIC SUAD
发明人： EFENDIC SUAD
IPC分类号： A01K67/027 , A61K45/00 , A61P3/08 , A61P5/50 , A61P43/00 , C12N5/10 , C12N9/88 , C12N15/09 , C12N15/85 , C12Q1/68
CPC分类号： C12Q1/6883 , A01K2217/05 , A01K2217/075 , A01K2267/0306 , A01K2267/0362 , A01K2267/0393 , C12N9/88 , C12N15/8509 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates to a method of detecting a disorder in carbohydrate metabolism, such as type II diabetes (NIDDM), by detecting a promoter of an adenylate cyclase III gene, the promoter having enhanced activity. The present invention also relates to a promoter from an adenylate cyclase III gene having enhanced activity, and isolated DNA molecules containing this promoter. The promoter having enhanced activity can be part of a transgenic animal. In another embodiment, the invention relates to a method of treating a patient having a disorder in carbohydrate metabolism, such as type II diabetes (NIDDM), and a method of enhancing or restoring a patient's response to insulin. Each of these methods includes administering to the patient a down regulator, an antagonist, or an inhibitor of expression of the adenylate cyclase III gene, or of the activity of one of its gene products.
摘要翻译：本发明涉及通过检测腺苷酸环化酶III基因的启动子来检测碳水化合物代谢紊乱如II型糖尿病（NIDDM）的方法，所述启动子具有增强的活性。本发明还涉及来自具有增强的活性的腺苷酸环化酶III基因的启动子和含有该启动子的分离的DNA分子。具有增强的活性的启动子可以是转基因动物的一部分。在另一个实施方案中，本发明涉及治疗患有糖代谢障碍例如II型糖尿病（NIDDM）的患者的方法，以及增强或恢复患者对胰岛素的应答的方法。这些方法中的每一种都包括向患者施用腺病毒环化酶III基因的下调，拮抗剂或表达抑制剂或其基因产物之一的活性。

5. 发明专利

HU0103147A2 PHARMACEUTICAL COMPOSITION COMPRISING GLP1 AND THEIR USE FOR THE TREATMENT OF FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME 未知
公开(公告)号：HU0103147A2
公开(公告)日：2002-01-28
申请号：HU0103147
申请日：1999-06-08
申请人： EFENDIC SUAD , HELLSTROEM PER
发明人： EFENDIC SUAD
IPC分类号： A61K38/04 , A61K38/26 , A61K38/31 , A61P1/00 , A61P1/06 , A61P1/14 , A61P43/00
摘要： The use of a gastrointestinal peptide hormone, selected from glucagon-like peptide-1 (GLP-1) and its derivatives having anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract, for the manufacture of a pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome, is new. Independent claims are also included for the following: (1) a pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome characterized in that it comprises a combination of at least one member selected from GLP-1 and its derivatives having anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract with one or two more other gastrointestinal peptide hormone(s) and their derivatives having such effects and properties together with additives; and (2) a method for the treatment of functional dyspepsia or irritable bowel syndrome or both in a human patient, comprising administering the composition of (1). ACTIVITY : Anti-inflammatory. MECHANISM OF ACTION : GLP-1 is a gastrointestinal peptide hormone with antisecretory effects and smooth muscle relaxatory properties within the gastrointestinal tract.

6. 发明专利

NO20006194D0 未知
公开(公告)号：NO20006194D0
公开(公告)日：2000-12-06
申请号：NO20006194
申请日：2000-12-06
申请人： HELLSTROEM PER , EFENDIC SUAD
发明人： HELLSTROEM PER , EFENDIC SUAD
IPC分类号： A61K38/04 , A61K38/26 , A61K38/31 , A61P1/00 , A61P1/06 , A61P1/14 , A61P43/00 , A61K
摘要： The use of a gastrointestinal peptide hormone, selected from glucagon-like peptide-1 (GLP-1) and its derivatives having anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract, for the manufacture of a pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome, is new. Independent claims are also included for the following: (1) a pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome characterized in that it comprises a combination of at least one member selected from GLP-1 and its derivatives having anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract with one or two more other gastrointestinal peptide hormone(s) and their derivatives having such effects and properties together with additives; and (2) a method for the treatment of functional dyspepsia or irritable bowel syndrome or both in a human patient, comprising administering the composition of (1). ACTIVITY : Anti-inflammatory. MECHANISM OF ACTION : GLP-1 is a gastrointestinal peptide hormone with antisecretory effects and smooth muscle relaxatory properties within the gastrointestinal tract.

7. 发明专利

DE69327309T2 未知
公开(公告)号：DE69327309T2
公开(公告)日：2000-07-13
申请号：DE69327309
申请日：1993-03-18
申请人： NOVO NORDISK AS , EFENDIC SUAD , GUTNIAK MARK
发明人： EFENDIC SUAD , GUTNIAK MARK , KIRK OLE
IPC分类号： A61K31/155 , A61K31/17 , A61K31/445 , A61K31/64 , A61K38/26 , A61P3/08 , A61P3/10
摘要： The invention employs GLP-1 (7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.

8. 发明专利

CA2321700C PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME AND NEW USE OF SUBSTANCES THEREIN 未知
公开(公告)号：CA2321700C
公开(公告)日：2011-05-03
申请号：CA2321700
申请日：1999-06-08
申请人： HELLSTROM PER , EFENDIC SUAD
发明人： HELLSTROM PER , EFENDIC SUAD
IPC分类号： A61K38/26 , A61K38/04 , A61K38/31 , A61P1/00 , A61P1/06 , A61P1/14 , A61P43/00
摘要： The invention relates to the new use of gastrointestinal peptide hormones selected from the class consisting of glucagon-like peptide-1 (GLP-1) and derivatives thereof having anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract for the manufacture of a pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome. The invention also relates to a pharmaceutical composition comprising a combination of at least one member selected from said class consisting of GLP-1 and derivatives thereof with one or more other gastrointestinal peptide hormone(s) or derivative(s) thereof together with pharmacologically acceptable additives and to a method of treating functional dyspepsia or irritable bowel syndrome or both by administering an effective amount of at least one member of said class consisting of GLP-1 and derivatives thereof having effects and properties as mentioned above.

9. 发明专利

DE69327309T3 未知
公开(公告)号：DE69327309T3
公开(公告)日：2007-07-05
申请号：DE69327309
申请日：1993-03-18
申请人： NOVO NORDISK AS , EFENDIC SUAD , GUTNIAK MARK
发明人： EFENDIC SUAD , GUTNIAK MARK , KIRK OLE
IPC分类号： A61K38/26 , A61K31/155 , A61K31/17 , A61K31/445 , A61K31/64 , A61P3/08 , A61P3/10
摘要： The invention employs GLP-1 (7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.

10. 发明专利

AT187647T 未知
公开(公告)号：AT187647T
公开(公告)日：2000-01-15
申请号：AT93907820
申请日：1993-03-18
申请人： NOVO NORDISK AS , EFENDIC SUAD , GUTNIAK MARK
发明人： EFENDIC SUAD , GUTNIAK MARK , KIRK OLE
IPC分类号： A61K31/155 , A61K31/17 , A61K31/445 , A61K31/64 , A61K38/26 , A61P3/08 , A61P3/10
摘要： The invention employs GLP-1 (7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式